SGS is introducing new in vitro toxicology services at its Mississauga, Canada lab. The investment in instruments and expansion of the lab’s capabilities will allow SGS clients to establish toxicological profiles of bio/pharmaceuticals, medical devices, cosmetics and chemicals. 
 
The investment includes an expansion of existing cell/tissue culture capabilities, flow cytometry and mass spectrometry facilities, along with the introduction of high throughput screening, automation, and multiplexing technologies such as the MESO SECTOR S 600 for biomarker analysis. The suite of services covers more than 50 analytical techniques including dermal and ocular toxicity, cytotoxicity, genotoxicity, carcinogenicity, phototoxicity, endocrine disruption, hepatotoxicity and cardiotoxicity. The new service offerings will be available under both R&D and Good Laboratory Practice (OECD, FDA Part 58) study conditions.
 
“Recent technical advancements and new government regulations have led to the rapid development of new, cost effective testing for the establishment of drug, device, chemical and cosmetic safety,” said Dr. Alex Perieteanu, Director of Biopharmaceutical Services at SGS Canada.  “SGS is an organization with a strong global reputation for quality and integrity, and this investment aligns the laboratory with the three Rs – the principles of replacement, reduction and refinement – for more humane experimental research, and ensures patient safety and accelerating product development.”
 
SGS’s Mississauga facility provides contract testing services within the biopharmaceutical, pharmaceutical, bioanalytical, and medical device segments. The facility is Health Canada and FDA registered and carries ISO 9001:2015 and ISO 13485:2016 accreditations.